Tiragolumab for Carcinoma, Transitional Cell

Phase-Based Progress Estimates
M D Anderson Cancer Center, Houston, TX
Carcinoma, Transitional Cell+1 More
Tiragolumab - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing if a combination of two drugs can help control bladder cancer before surgery. This clinical trial is testing tiragolumab as a treatment for carcinoma, transitional cell. All patients in the trial will receive tiragolumab, and there will be no placebo group. This clinical trial is free for participants. Tiragolumab has previously been approved by the FDA for a different condition.

Eligible Conditions

  • Carcinoma, Transitional Cell
  • Metastatic Malignancy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Carcinoma, Transitional Cell

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Through study completion, an average of 1 year

Year 1
To evaluate overall survival (OS).
To evaluate relapse-free survival (RFS)

Trial Safety

Safety Progress

1 of 3

Other trials for Carcinoma, Transitional Cell

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Experimental Treatment

10 Total Participants · 2 Treatment Groups

Primary Treatment: Tiragolumab · No Placebo Group · Phase < 1

Experimental Group · 1 Intervention: Atezolizumab · Intervention Types: Drug
Experimental Group · 1 Intervention: Tiragolumab · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1 year
Closest Location: M D Anderson Cancer Center · Houston, TX
Photo of Houston 1Photo of Houston 2Photo of Houston 3
2003First Recorded Clinical Trial
25 TrialsResearching Carcinoma, Transitional Cell
465 CompletedClinical Trials

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,772 Previous Clinical Trials
1,794,719 Total Patients Enrolled
16 Trials studying Carcinoma, Transitional Cell
1,089 Patients Enrolled for Carcinoma, Transitional Cell
Padmanee Sharma, MD, PhDPrincipal InvestigatorM.D. Anderson Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are able to comply with the study protocol.
Tissue from the bladder is removed by TURBT at the MD Anderson Cancer Center.
You are eligible for R0 resection with curative intent at the time of screening, as confirmed by the operating attending surgeon and involved medical oncologist prior to study enrollment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.